Robert Knoerl1, Emanuele Mazzola2, Fangxin Hong2, Elahe Salehi3, Nadine McCleary3, Jennifer Ligibel3, Kaitlen Reyes3, Donna L Berry4. 1. Dana-Farber Cancer Institute, Boston, MA, USA. robert_knoerl@dfci.harvard.edu. 2. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA. 3. Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 4. Biobehavioral Nursing and Health Informatics, University of Washington, Seattle, WA, USA.
Abstract
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) negatively affects physical function and chemotherapy dosing, yet, clinicians infrequently document CIPN assessment and/or adhere to evidence-based CIPN management in practice. The primary aims of this two-phase, pre-posttest study were to explore the impact of a CIPN clinician decision support algorithm on clinicians' frequency of CIPN assessment documentation and adherence to evidence-based management. METHODS: One hundred sixty-two patients receiving neurotoxic chemotherapy (e.g., taxanes, platinums, or bortezomib) answered patient-reported outcome measures on CIPN severity and interference prior to three clinic visits at breast, gastrointestinal, or multiple myeloma outpatient clinics (n = 81 usual care phase [UCP], n = 81 algorithm phase [AP]). During the AP, study staff delivered a copy of the CIPN assessment and management algorithm to clinicians (N = 53) prior to each clinic visit. Changes in clinicians' CIPN assessment documentation (i.e., index of numbness, tingling, and/or CIPN pain documentation) and adherence to evidence-based management at the third clinic visit were compared between the AP and UCP using Pearson's chi-squared test. RESULTS: Clinicians' frequency of adherence to evidence-based CIPN management was higher in the AP (29/52 [56%]) than the UCP (20/46 [43%]), but the change was not statistically significant (p = 0.31). There were no improvements in clinicians' CIPN assessment frequency during the AP (assessment index = 0.5440) in comparison to during the UCP (assessment index = 0.6468). CONCLUSIONS: Implementation of a clinician-decision support algorithm did not significantly improve clinicians' CIPN assessment documentation or adherence to evidence-based management. Further research is needed to develop theory-based implementation interventions to bolster the frequency of CIPN assessment and use of evidence-based management strategies in practice. TRIAL REGISTRATION: ClinicalTrials.Gov, NCT03514680 . Registered 21 April 2018.
BACKGROUND: Chemotherapy-induced peripheral neuropathy (CIPN) negatively affects physical function and chemotherapy dosing, yet, clinicians infrequently document CIPN assessment and/or adhere to evidence-based CIPN management in practice. The primary aims of this two-phase, pre-posttest study were to explore the impact of a CIPN clinician decision support algorithm on clinicians' frequency of CIPN assessment documentation and adherence to evidence-based management. METHODS: One hundred sixty-two patients receiving neurotoxic chemotherapy (e.g., taxanes, platinums, or bortezomib) answered patient-reported outcome measures on CIPN severity and interference prior to three clinic visits at breast, gastrointestinal, or multiple myelomaoutpatient clinics (n = 81 usual care phase [UCP], n = 81 algorithm phase [AP]). During the AP, study staff delivered a copy of the CIPN assessment and management algorithm to clinicians (N = 53) prior to each clinic visit. Changes in clinicians' CIPN assessment documentation (i.e., index of numbness, tingling, and/or CIPN pain documentation) and adherence to evidence-based management at the third clinic visit were compared between the AP and UCP using Pearson's chi-squared test. RESULTS: Clinicians' frequency of adherence to evidence-based CIPN management was higher in the AP (29/52 [56%]) than the UCP (20/46 [43%]), but the change was not statistically significant (p = 0.31). There were no improvements in clinicians' CIPN assessment frequency during the AP (assessment index = 0.5440) in comparison to during the UCP (assessment index = 0.6468). CONCLUSIONS: Implementation of a clinician-decision support algorithm did not significantly improve clinicians' CIPN assessment documentation or adherence to evidence-based management. Further research is needed to develop theory-based implementation interventions to bolster the frequency of CIPN assessment and use of evidence-based management strategies in practice. TRIAL REGISTRATION: ClinicalTrials.Gov, NCT03514680 . Registered 21 April 2018.
Entities:
Keywords:
Algorithms; Chemotherapy-induced peripheral neuropathy; Clinical; Decision Support systems; Documentation; Neoplasms; Peripheral nervous system diseases
Authors: Amylou C Dueck; Tito R Mendoza; Sandra A Mitchell; Bryce B Reeve; Kathleen M Castro; Lauren J Rogak; Thomas M Atkinson; Antonia V Bennett; Andrea M Denicoff; Ann M O'Mara; Yuelin Li; Steven B Clauser; Donna M Bryant; James D Bearden; Theresa A Gillis; Jay K Harness; Robert D Siegel; Diane B Paul; Charles S Cleeland; Deborah Schrag; Jeff A Sloan; Amy P Abernethy; Deborah W Bruner; Lori M Minasian; Ethan Basch Journal: JAMA Oncol Date: 2015-11 Impact factor: 31.777
Authors: Charles L Loprinzi; Christina Lacchetti; Jonathan Bleeker; Guido Cavaletti; Cynthia Chauhan; Daniel L Hertz; Mark R Kelley; Antoinette Lavino; Maryam B Lustberg; Judith A Paice; Bryan P Schneider; Ellen M Lavoie Smith; Mary Lou Smith; Thomas J Smith; Nina Wagner-Johnston; Dawn L Hershman Journal: J Clin Oncol Date: 2020-07-14 Impact factor: 44.544
Authors: Dawn L Hershman; Cathee Till; Jason D Wright; Danielle Awad; Scott D Ramsey; William E Barlow; Lori M Minasian; Joseph Unger Journal: J Clin Oncol Date: 2016-06-20 Impact factor: 44.544
Authors: T J Postma; N K Aaronson; J J Heimans; M J Muller; J G Hildebrand; J Y Delattre; K Hoang-Xuan; M Lantéri-Minet; R Grant; R Huddart; C Moynihan; J Maher; R Lucey Journal: Eur J Cancer Date: 2005-04-14 Impact factor: 9.162
Authors: Heather Greenlee; Dawn L Hershman; Zaixing Shi; Marilyn L Kwan; Isaac J Ergas; Janise M Roh; Lawrence H Kushi Journal: J Natl Cancer Inst Date: 2016-10-28 Impact factor: 11.816
Authors: Kelley C Wood; Mackenzi Pergolotti; Tim Marshall; Heather J Leach; Julia L Sharp; Grace Campbell; Grant R Williams; Jack B Fu; Tiffany D Kendig; Nancy Howe; Anita Bundy Journal: Support Care Cancer Date: 2022-05-26 Impact factor: 3.359